MCID: PRM108
MIFTS: 45

Primary Progressive Multiple Sclerosis

Categories: Neuronal diseases, Genetic diseases

Aliases & Classifications for Primary Progressive Multiple Sclerosis

MalaCards integrated aliases for Primary Progressive Multiple Sclerosis:

Name: Primary Progressive Multiple Sclerosis 12 52 14
Multiple Sclerosis, Primary Progressive 69
Primary-Progressive Ms 12
Ppms 12

Classifications:



External Ids:

Disease Ontology 12 DOID:0050784
MeSH 42 D020528
SNOMED-CT 64 428700003
UMLS 69 C0751964

Summaries for Primary Progressive Multiple Sclerosis

Disease Ontology : 12 A multiple sclerosis that is characterized by steady worsening of neurologic functioning, without any distinct relapses or periods of remission. The rate of progression may vary over time, with occasional plateaus or temporary improvements, but the progression is continuous.

MalaCards based summary : Primary Progressive Multiple Sclerosis, also known as multiple sclerosis, primary progressive, is related to asthma and mental retardation, x-linked, syndromic 13. An important gene associated with Primary Progressive Multiple Sclerosis is IFNB1 (Interferon Beta 1), and among its related pathways/superpathways are Innate Immune System and Cytokine Signaling in Immune system. The drugs Dimethyl fumarate and 4-Aminopyridine have been mentioned in the context of this disorder. Affiliated tissues include brain, b cells and t cells, and related phenotypes are hematopoietic system and cellular

Related Diseases for Primary Progressive Multiple Sclerosis

Diseases in the Primary Progressive Multiple Sclerosis family:

Multiple Sclerosis 4 Multiple Sclerosis 3
Multiple Sclerosis 2 Multiple Sclerosis 5
Secondary Progressive Multiple Sclerosis

Diseases related to Primary Progressive Multiple Sclerosis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 123)
id Related Disease Score Top Affiliating Genes
1 asthma 29.1 ICAM1 IL10 MMP9 TNF VCAM1
2 mental retardation, x-linked, syndromic 13 11.6
3 fetal methylmercury syndrome 11.0
4 jamaican vomiting sickness 11.0
5 pure autonomic failure 10.8 IL10 TNF
6 acute ackee fruit intoxication 10.8 IL10 TNF
7 multiple familial trichoepithelioma 10.7 IL10 TNF
8 basidiobolomycosis 10.7 IL10 TNF
9 lagophthalmos 10.7 IL10 TNF
10 drug rash with eosinophilia and systemic symptoms 10.7 IL10 MMP9
11 type 1 papillary adenoma of the kidney 10.7 IL10 TNF
12 burning mouth syndrome 10.7 IFNB1 TNF
13 endosalpingiosis 10.7 IL10 TNF
14 urethral intrinsic sphincter deficiency 10.7 MMP9 TNF
15 idiopathic dilatation of the pulmonary artery 10.6 IL10 TNF
16 ethmoid sinus adenocarcinoma 10.6 IL10 TNF
17 liver leiomyoma 10.6 IL10 TNF
18 tarsal tunnel syndrome 10.6 IL10 TNF
19 halal setton wang syndrome 10.6 ICAM1 TNF
20 endocervical type cervical mucinous adenocarcinoma 10.5 IL10 MMP9 TNF
21 burn scar 10.5 IL10 MMP9 TNF
22 plantar wart 10.5 IL10 TNF
23 cauda equina syndrome 10.5 IFNB1 TNF
24 spindle cell hemangioma 10.5 ICAM1 IL10 TNF
25 conduct disorder 10.5 ICAM1 IL10 TNF
26 optic nerve hypoplasia 10.5 IL10 MMP9 TNF
27 hypospadias 10.5 ICAM1 IL10 TNF
28 cogan-reese syndrome 10.5 IFNB1 MBP
29 dehydration polycythemia 10.5 ICAM1 IL10 TNF
30 vulva fibroepithelial polyp 10.5 IL10 MMP9 TNF
31 pulmonary embolism 10.5 IL10 MMP9 TNF
32 acute interstitial pneumonia 10.5 ICAM1 IL10 TNF
33 diamond-blackfan anemia 1 10.5 IL10 MMP9 TNF
34 ostertagiasis 10.5 IFNB1 IL10 TNF
35 pyelonephritis 10.5 ICAM1 IL10 TNF
36 churg-strauss syndrome 10.5 ICAM1 IL10 TNF
37 alopecia 10.5 ICAM1 IL10 TNF
38 benign eccrine breast spiradenoma 10.5 ICAM1 IL10 TNF
39 autoimmune polyglandular syndrome type 3 10.5 TNF VCAM1
40 cerebellar disease 10.5 ICAM1 IL10 TNF
41 granulomatous orchitis 10.5 IL10 MMP9 TNF
42 scabies 10.5 ICAM1 IL10 TNF
43 geniculate ganglionitis 10.5 ICAM1 IL10 TNF
44 esophageal candidiasis 10.4 ICAM1 IL10 TNF
45 lymphomatous thyroiditis 10.4 ICAM1 VCAM1
46 pellagra like syndrome 10.4 MMP9 MOG
47 heart lymphoma 10.4 ICAM1 VCAM1
48 marginal corneal ulcer 10.4 ICAM1 VCAM1
49 tracheal stenosis 10.3 MBP MOG TNF
50 cellular schwannoma 10.3 MBP MOG TNF

Graphical network of the top 20 diseases related to Primary Progressive Multiple Sclerosis:



Diseases related to Primary Progressive Multiple Sclerosis

Symptoms & Phenotypes for Primary Progressive Multiple Sclerosis

MGI Mouse Phenotypes related to Primary Progressive Multiple Sclerosis:

44 (show all 12)
id Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 10.22 CSF1R ICAM1 IFNB1 IL10 IL7R MBP
2 cellular MP:0005384 10.21 CSF1R ICAM1 IL10 IL7R MBP MMP9
3 homeostasis/metabolism MP:0005376 10.2 OMG PLP1 S100B TNF VCAM1 CSF1R
4 immune system MP:0005387 10.17 CSF1R ICAM1 IFNB1 IL10 IL7R MBP
5 growth/size/body region MP:0005378 10.15 PLP1 TNF VCAM1 CSF1R ICAM1 IL10
6 nervous system MP:0003631 9.97 CSF1R ICAM1 IFNB1 IL10 MBP MMP9
7 muscle MP:0005369 9.88 ICAM1 IL10 MMP9 MOG PLP1 TNF
8 neoplasm MP:0002006 9.85 ICAM1 IFNB1 IL10 IL7R MMP9 TNF
9 no phenotypic analysis MP:0003012 9.73 CSF1R IFNB1 IL10 OMG TNF VCAM1
10 normal MP:0002873 9.7 CSF1R IFNB1 IL10 IL7R MBP OMG
11 reproductive system MP:0005389 9.5 CSF1R IL10 MBP MMP9 PLP1 TNF
12 vision/eye MP:0005391 9.17 ICAM1 IL10 MBP MMP9 MOG PLP1

Drugs & Therapeutics for Primary Progressive Multiple Sclerosis

Drugs for Primary Progressive Multiple Sclerosis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 185)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Dimethyl fumarate Approved, Investigational Phase 4,Phase 3,Phase 2 624-49-7 5271565 637568
2
4-Aminopyridine Approved Phase 4,Phase 3 504-24-5 1727
3
Prednisone Approved, Vet_approved Phase 4 53-03-2 5865
4 Anti-Inflammatory Agents Phase 4,Phase 3,Phase 1,Phase 2
5 Antineoplastic Agents, Hormonal Phase 4,Phase 3,Phase 2,Phase 1
6 glucocorticoids Phase 4,Phase 3,Phase 2,Phase 1
7 Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1
8 Hormones Phase 4,Phase 3,Phase 2,Phase 1
9 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1
10 Dermatologic Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
11 Immunosuppressive Agents Phase 4,Phase 3,Phase 2,Early Phase 1
12 Potassium Channel Blockers Phase 4,Phase 3
13
rituximab Approved Phase 2, Phase 3,Phase 1 174722-31-7 10201696
14
Methylprednisolone Approved, Vet_approved Phase 3,Phase 2,Phase 1 83-43-2 6741
15
Prednisolone Approved, Vet_approved Phase 3,Phase 2,Phase 1 50-24-8 5755
16
Cyclophosphamide Approved, Investigational Phase 3 50-18-0, 6055-19-2 2907
17
Natalizumab Approved, Investigational Phase 3,Phase 2,Phase 1 189261-10-7
18
Morphine Approved, Investigational Phase 3 57-27-2 5288826
19
Hydroxyurea Approved Phase 2, Phase 3 127-07-1 3657
20
Biotin Approved, Nutraceutical Phase 3 58-85-5 171548
21
Epigallocatechin gallate Investigational Phase 2, Phase 3 989-51-5 65064
22 Antirheumatic Agents Phase 2, Phase 3, Phase 1, Early Phase 1
23 Neuroprotective Agents Phase 2, Phase 3, Phase 1
24 Protective Agents Phase 2, Phase 3, Phase 1
25 Antiemetics Phase 3,Phase 2,Phase 1
26 Autonomic Agents Phase 3,Phase 2,Phase 1
27 Gastrointestinal Agents Phase 3,Phase 2,Phase 1
28 Methylprednisolone acetate Phase 3,Phase 2,Phase 1
29 Methylprednisolone Hemisuccinate Phase 3,Phase 2,Phase 1
30 Peripheral Nervous System Agents Phase 3,Phase 1,Phase 2
31 Prednisolone acetate Phase 3,Phase 2,Phase 1
32 Prednisolone hemisuccinate Phase 3,Phase 2,Phase 1
33 Prednisolone phosphate Phase 3,Phase 2,Phase 1
34 Antioxidants Phase 2, Phase 3,Phase 1
35 Alkylating Agents Phase 3
36 Vaccines Phase 2, Phase 3,Phase 1
37 Nucleic Acid Synthesis Inhibitors Phase 2, Phase 3,Early Phase 1
38 Fingolimod Hydrochloride Phase 3
39
Catechin Nutraceutical Phase 2, Phase 3 154-23-4 9064
40
Epicatechin Investigational, Nutraceutical Phase 2, Phase 3 490-46-0 72276
41
Epigallocatechin Experimental, Nutraceutical Phase 2, Phase 3 970-74-1 72277
42 Vitamin B7 Nutraceutical Phase 3
43
Dopamine Approved Phase 2,Phase 1 51-61-6, 62-31-7 681
44
Ibudilast Approved, Investigational Phase 2 50847-11-5 3671
45
Daclizumab Approved, Investigational Phase 2 152923-56-3
46
Acetylcysteine Approved, Investigational Phase 2,Phase 1 616-91-1 12035
47
Hydroxychloroquine Approved Phase 2 118-42-3 3652
48
Norethindrone Approved Phase 2 68-22-4 6230
49
Zinc Approved Phase 1, Phase 2 7440-66-6 32051 23994
50
Domperidone Approved, Investigational, Vet_approved Phase 2 57808-66-9 3151

Interventional clinical trials:

(show top 50) (show all 91)

id Name Status NCT ID Phase Drugs
1 Pharmacokinetics of DMF and the Effects of DMF on Exploratory Biomarkers Completed NCT02683863 Phase 4 BG00012 (DMF) (Tecfidera®.)
2 A Double Blind, Randomized, Placebo Controlled, Crossover Study of the Effectiveness of Oral Fampridine in Improving Upper Limb Function in Progressive Multiple Sclerosis Active, not recruiting NCT02208050 Phase 4 Fampridine;Placebo
3 Oral Prednisone Taper Versus Placebo for the Treatment of Acute Relapses in Multiple Sclerosis Terminated NCT01411514 Phase 4 Prednisone;Placebo
4 A Study to Evaluate the Safety and Efficacy of Rituximab in Adults With Primary Progressive Multiple Sclerosis Completed NCT00087529 Phase 2, Phase 3 placebo;rituximab
5 Neurophysiological Study of Sativex in Multiple Sclerosis (MS) Spasticity Completed NCT01538225 Phase 3 Sativex®;Placebo
6 Sunphenon in Progressive Forms of Multiple Sclerosis Completed NCT00799890 Phase 2, Phase 3 Sunphenon EGCG;Placebo
7 A Safety and Efficacy Study of Oral Prolonged-Release Fampridine (BIIB041) in Japanese Participants With Multiple Sclerosis Completed NCT01917019 Phase 3 Placebo;BIIB041 (fampridine)
8 Efficacy of Cyclophosphamide Versus Methylprednisolone in Patients With Secondary Progressive Multiple Sclerosis Completed NCT00241254 Phase 3 Cyclophosphamide (drug);Methylprednisolone (drug)
9 Study to Explore the Mechanism of Action of Ocrelizumab and B-Cell Biology in Participants With Relapsing Multiple Sclerosis (RMS) or Primary Progressive Multiple Sclerosis (PPMS) Recruiting NCT02688985 Phase 3 Ocrelizumab
10 A Phase 3 Study to Compare Efficacy and Safety of Masitinib to Placebo in the Treatment of Patients With Primary Progressive or Relapse-free Secondary Progressive Multiple Sclerosis Recruiting NCT01433497 Phase 2, Phase 3 masitinib;placebo
11 Effect of MD1003 in Progressive Multiple Sclerosis (SPI2) Recruiting NCT02936037 Phase 3 MD1003 100mg capsule;PLACEBO
12 A Study of Ocrelizumab in Participants With Primary Progressive Multiple Sclerosis Active, not recruiting NCT01194570 Phase 3 Ocrelizumab
13 Effect of MD1003 in Chronic Visual Loss Related to Optic Neuritis in Multiple Sclerosis Active, not recruiting NCT02220244 Phase 3 MD1003 100mg capsule
14 A Study of NeuroVax™, a Therapeutic TCR Peptide Vaccine for SPMS of Multiple Sclerosis Not yet recruiting NCT02057159 Phase 2, Phase 3
15 This Was an Open-label, Single-arm Extension Study (CFTY720D2306E1) to a Double-blind, Randomized Multicenter, Placebo-controlled, Parallel-group Core Study (CFTY720D2306) in PPMS. Terminated NCT00731692 Phase 3 FTY720;Placebo
16 Hydroxyurea in Primary Progressive Multiple Sclerosis Terminated NCT01103583 Phase 2, Phase 3 Hydroxyurea
17 A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Participants With Secondary Progressive Multiple Sclerosis Terminated NCT01416181 Phase 3 natalizumab;Placebo
18 BG00012 and Delay of Disability Progression in Secondary Progressive Multiple Sclerosis Terminated NCT02430532 Phase 3 dimethyl fumarate
19 Efficacy, Safety and Tolerability of Andrographolides Versus Placebo in Patients With Progressive Forms of MS Unknown status NCT02273635 Phase 1, Phase 2 Andrographolides;placebo
20 The Effects of Erythropoietin on Clinical Disability and Brain Pathology in Patients With Progressive Multiple Sclerosis Unknown status NCT01144117 Phase 2 Erythropoietin
21 Intrathecal Rituximab in Progressive Multiple Sclerosis Unknown status NCT02545959 Phase 2 Rituximab IT;methylprednisolone IV;Rituximab IV
22 Masitinib in Patients With Primary Progressive Multiple Sclerosis (PPMS) or Relapse-free Secondary Progressive Multiple Sclerosis (SPMS) Completed NCT01450488 Phase 2 masitinib;masitinib
23 Natalizumab Treatment of Progressive Multiple Sclerosis Completed NCT01077466 Phase 2 Natalizumab
24 Safety Study of an Immunomodulating Microparticle to Treat Progressive Multiple Sclerosis Completed NCT01191996 Phase 1, Phase 2
25 Safety, Tolerability and Activity Study of Ibudilast in Subjects With Progressive Multiple Sclerosis Completed NCT01982942 Phase 2 ibudilast;Placebo
26 Zenapax (Daclizumab) to Treat Relapsing Remitting Multiple Sclerosis Completed NCT00071838 Phase 2 Daclizumab
27 Autologous Mesenchymal Stem Cells From Adipose Tissue in Patients With Secondary Progressive Multiple Sclerosis Completed NCT01056471 Phase 1, Phase 2
28 T Cell Vaccination in Patients With Progressive Multiple Sclerosis Completed NCT01448252 Phase 1, Phase 2
29 Cyclic Oral Methylprednisolone Trial in Multiple Sclerosis Completed NCT01305837 Phase 2 methylprednisolone
30 Intrathecal Therapy With Monoclonal Antibodies in Progressive Multiple Sclerosis Completed NCT01719159 Phase 2 Rituximab
31 Progressive Muscle Relaxation Effect on Sleep Quality, Depression and Stress in People With Multiple Sclerosis Completed NCT02673827 Phase 2
32 Dimethyl Fumarate Treatment of Primary Progressive Multiple Sclerosis Recruiting NCT02959658 Phase 2 Dimethyl Fumarate;Placebo Oral Capsule
33 Hydroxychloroquine in Primary Progressive Multiple Sclerosis Recruiting NCT02913157 Phase 2 Hydroxychloroquine
34 Estriol Treatment in Multiple Sclerosis (MS): Effect on Cognition Recruiting NCT01466114 Phase 2 estriol;Norethindrone
35 ACTH in Progressive Forms of MS Recruiting NCT01950234 Phase 2 ACTH;Placebo
36 Intranasal Insulin for Improving Cognitive Function in Multiple Sclerosis Recruiting NCT02988401 Phase 1, Phase 2 Insulin;Placebo
37 Safety and Tolerability of Quetiapine in Multiple Sclerosis Recruiting NCT02087631 Phase 1, Phase 2 Extended-release quetiapine fumarate
38 A Study of Oxidative Pathways in MS Fatigue Recruiting NCT02804594 Phase 2 N-acetyl cysteine;Placebo
39 Microglial Activation Positron Emission Tomography (PET) Brain Imaging in Multiple Sclerosis and Alzheimer's Disease Recruiting NCT02649985 Phase 1, Phase 2 [F-18]PBR06
40 Domperidone in Secondary Progressive Multiple Sclerosis (SPMS) Recruiting NCT02308137 Phase 2 Domperidone
41 Double Blind Placebo-Controlled Phase I/II Clinical Trial of Idebenone in Patients With Primary Progressive Multiple Sclerosis (IPPoMS) Active, not recruiting NCT00950248 Phase 1, Phase 2 Idebenone
42 A Phase 2 Clinical Study in Subjects With Primary Progressive Multiple Sclerosis to Assess the Efficacy, Safety and Tolerability of Two Oral Doses of Laquinimod Either of 0.6 mg/Day or 1.5mg/Day (Experimental Drug) as Compared to Placebo Active, not recruiting NCT02284568 Phase 2 Laquinimod;Placebo
43 Repetitive Transcranial Magnetic Stimulation for Lower Limb Spasticity in Multiple Sclerosis Patients Active, not recruiting NCT02747914 Phase 1, Phase 2
44 MS-SMART: Multiple Sclerosis-Secondary Progressive Multi-Arm Randomisation Trial Active, not recruiting NCT01910259 Phase 2 Amiloride;Riluzole;Fluoxetine;Placebo
45 Idebenone for Primary Progressive Multiple Sclerosis Enrolling by invitation NCT01854359 Phase 1, Phase 2 Idebenone
46 Cannabis for Spasticity in Multiple Sclerosis Terminated NCT00682929 Phase 1, Phase 2 Inhaled Cannabis;Oral THC;Placebo
47 Cannabis for Spasticity in Multiple Sclerosis Terminated NCT00260741 Phase 1, Phase 2 Smoked Cannabis
48 Evaluation of Efficiency of Ritalin in Multiple Sclerosis (MS) Patients Unknown status NCT00220493 Phase 1 Ritalin
49 Nutrition, Neuromuscular Electrical Stimulation (NMES) and Secondary Progressive Multiple Sclerosis (SPMS) Completed NCT01381354 Phase 1
50 A Phase 1 Trial of Intrathecal Rituximab for Progressive Multiple Sclerosis Patients Completed NCT02253264 Phase 1 Rituximab

Search NIH Clinical Center for Primary Progressive Multiple Sclerosis

Genetic Tests for Primary Progressive Multiple Sclerosis

Anatomical Context for Primary Progressive Multiple Sclerosis

MalaCards organs/tissues related to Primary Progressive Multiple Sclerosis:

39
Brain, B Cells, T Cells, Spinal Cord, Lymph Node

Publications for Primary Progressive Multiple Sclerosis

Articles related to Primary Progressive Multiple Sclerosis:

(show top 50) (show all 82)
id Title Authors Year
1
Smoking does not influence disability accumulation in primary progressive multiple sclerosis. ( 28239937 )
2017
2
Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis. ( 28002688 )
2017
3
A contemporary profile of primary progressive multiple sclerosis participants from the NARCOMS Registry. ( 28524746 )
2017
4
CSF profile in primary progressive multiple sclerosis: Re-exploring the basics. ( 28797088 )
2017
5
Altered neural mechanisms of cognitive control in patients with primary progressive multiple sclerosis: An effective connectivity study. ( 28205364 )
2017
6
A composite measure to explore visual disability in primary progressive multiple sclerosis. ( 28607759 )
2017
7
Primary progressive multiple sclerosis presenting with severe predominant cognitive impairment and psychiatric symptoms: A challenging case. ( 28401768 )
2017
8
Aberrant expression of I^-catenin in CD4(+) T cells isolated from primary progressive multiple sclerosis patients. ( 28578105 )
2017
9
FDA approves first drug for primary progressive multiple sclerosis. ( 28450720 )
2017
10
Performance of 2010 McDonald criteria and 2016 MAGNIMS guidelines in the diagnosis of primary progressive multiple sclerosis. ( 28939685 )
2017
11
Primary Progressive Multiple Sclerosis: Putting Together the Puzzle. ( 28620346 )
2017
12
CXCL10 and CXCL13 chemokines in patients with relapsing remitting and primary progressive multiple sclerosis. ( 28870573 )
2017
13
Synchronization and variability imbalance underlie cognitive impairment in primary-progressive multiple sclerosis. ( 28429774 )
2017
14
The MRZ reaction in primary progressive multiple sclerosis. ( 28166789 )
2017
15
Primary Progressive Multiple Sclerosis Evolving From Radiologically Isolated Syndrome. ( 26599831 )
2016
16
Two cases of relapses in primary progressive multiple sclerosis after fingolimod withdrawal. ( 27159986 )
2016
17
CSF1R-related leukoencephalopathy mimicking primary progressive multiple sclerosis. ( 27314966 )
2016
18
Anti-SPAG16 antibodies in primary progressive multiple sclerosis are associated with an elevated progression index. ( 26706657 )
2016
19
Primary progressive multiple sclerosis--why we are failing. ( 26827076 )
2016
20
Primary progressive multiple sclerosis: current therapeutic strategies and future perspectives. ( 27813441 )
2016
21
Cognitive impairment and magnetic resonance imaging correlates in primary progressive multiple sclerosis. ( 27778334 )
2016
22
Oral fingolimod in primary progressive multiple sclerosis (INFORMS): a phase 3, randomised, double-blind, placebo-controlled trial. ( 26827074 )
2016
23
Anti-inflammatory nutritional intervention in patients with relapsing-remitting and primary-progressive multiple sclerosis: A pilot study. ( 26785711 )
2016
24
A significant decrease in diagnosis of primary progressive multiple sclerosis: A cohort study. ( 27072687 )
2016
25
Retinal degeneration in primary-progressive multiple sclerosis: A role for cortical lesions? ( 26993116 )
2016
26
Lack of efficacy of mitoxantrone in primary progressive Multiple Sclerosis irrespective of pharmacogenetic factors: a multi-center, retrospective analysis. ( 25468777 )
2015
27
Gray Matter Correlates of Cognitive Performance Differ between Relapsing-Remitting and Primary-Progressive Multiple Sclerosis. ( 26485710 )
2015
28
Risk Factors Associated with the Onset of Relapsing-Remitting and Primary Progressive Multiple Sclerosis: A Systematic Review. ( 25802867 )
2015
29
Cognitive impairment in a population-based study of patients with multiple sclerosis: differences between late relapsing-remitting, secondary progressive and primary progressive multiple sclerosis. ( 25903918 )
2015
30
Association of Deep Gray Matter Damage With Cortical and Spinal Cord Degeneration in Primary Progressive Multiple Sclerosis. ( 26457955 )
2015
31
Brain-Specific Cytoskeletal Damage Markers in Cerebrospinal Fluid: Is There a Common Pattern between Amyotrophic Lateral Sclerosis and Primary Progressive Multiple Sclerosis? ( 26263977 )
2015
32
Brain atrophy and physical disability in primary progressive multiple sclerosis: A volumetric study. ( 26246109 )
2015
33
Multimodal neurophysiological evaluation of primary progressive multiple sclerosis - An increasingly valid biomarker, with limits. ( 26590670 )
2015
34
Paroxetine-Related Adult-Onset Tic Disorder: A Presentation of Primary Progressive Multiple Sclerosis. ( 26222974 )
2015
35
Melatonin treatment improves primary progressive multiple sclerosis: a case report. ( 25546814 )
2015
36
Evidence for early neurodegeneration in the cervical cord of patients with primary progressive multiple sclerosis. ( 25863355 )
2015
37
Analysis of genes, pathways and networks involved in disease severity and age at onset in primary-progressive multiple sclerosis. ( 25583839 )
2015
38
PDE7 inhibitor TC3.6 ameliorates symptomatology in a model of primary progressive multiple sclerosis. ( 25994655 )
2015
39
Evaluation of Study and Patient Characteristics of Clinical Studies in Primary Progressive Multiple Sclerosis: A Systematic Review. ( 26393519 )
2015
40
Efficient generation of myelinating oligodendrocytes from primary progressive multiple sclerosis patients by induced pluripotent stem cells. ( 25254339 )
2014
41
Levels of soluble TNF-RII are increased in serum of patients with primary progressive multiple sclerosis. ( 24794503 )
2014
42
Electrophysiological markers and predictors of the disease course in primary progressive multiple sclerosis. ( 23756680 )
2014
43
Adult-onset vanishing white matter disease as differential diagnosis of primary progressive multiple sclerosis: A case report. ( 25135182 )
2014
44
Genetics of primary progressive multiple sclerosis. ( 24507520 )
2014
45
Validating predictors of disease progression in a large cohort of primary-progressive multiple sclerosis based on a systematic literature review. ( 24651401 )
2014
46
Modelling the natural history of primary progressive multiple sclerosis. ( 24828900 )
2014
47
Epstein-barr virus in the central nervous system and cervical lymph node of a patient with primary progressive multiple sclerosis. ( 24918642 )
2014
48
Retraction notice: Language abilities of patients with primary progressive multiple sclerosis: A preliminary group and case investigation. ( 24766406 )
2014
49
Temporal and spatial evolution of grey matter atrophy in primary progressive multiple sclerosis. ( 24099844 )
2014
50
Hereditary diffuse leukoencephalopathy with spheroids with phenotype of primary progressive multiple sclerosis. ( 25311247 )
2014

Variations for Primary Progressive Multiple Sclerosis

Expression for Primary Progressive Multiple Sclerosis

Search GEO for disease gene expression data for Primary Progressive Multiple Sclerosis.

Pathways for Primary Progressive Multiple Sclerosis

Pathways related to Primary Progressive Multiple Sclerosis according to GeneCards Suite gene sharing:

(show all 29)
id Super pathways Score Top Affiliating Genes
1
Show member pathways
13.86 CSF1R ICAM1 IFNB1 IL10 IL7R MMP9
2
Show member pathways
13.15 CSF1R ICAM1 IFNB1 IL10 IL7R MMP9
3 12.03 IL10 PLP1 TNF
4
Show member pathways
12.01 IFNB1 IL10 TNF
5 11.95 ICAM1 MMP9 TNF VCAM1
6 11.9 CSF1R IFNB1 TNF
7 11.85 IL10 IL7R TNF
8 11.82 ICAM1 MMP9 VCAM1
9 11.81 ICAM1 MMP9 TNF VCAM1
10 11.77 CSF1R IFNB1 IL10 IL7R
11 11.76 ICAM1 TNF VCAM1
12 11.75 CSF1R IL7R TNF
13 11.73 ICAM1 TNF VCAM1
14 11.73 ICAM1 MBP MMP9 OMG TNF
15 11.65 IL10 IL7R TNF
16 11.55 ICAM1 IL10 TNF VCAM1
17
Show member pathways
11.47 ICAM1 MMP9 TNF VCAM1
18 11.41 ICAM1 IL10 TNF
19 11.41 ICAM1 IL10 MMP9 TNF VCAM1
20 11.39 ICAM1 MMP9 TNF
21 11.31 ICAM1 IL10 TNF VCAM1
22 11.15 IFNB1 IL10 TNF
23 11.04 ICAM1 MMP9
24 11.01 IFNB1 TNF
25 11 ICAM1 IL10 TNF VCAM1
26 10.97 TNF VCAM1
27 10.9 CSF1R IFNB1 IL10 IL7R TNF
28 10.84 ICAM1 TNF VCAM1
29 10.46 MBP PLP1

GO Terms for Primary Progressive Multiple Sclerosis

Cellular components related to Primary Progressive Multiple Sclerosis according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 external side of plasma membrane GO:0009897 9.26 ICAM1 IL7R TNF VCAM1
2 extracellular space GO:0005615 9.23 ICAM1 IFNB1 IL10 MMP9 OMG S100B

Biological processes related to Primary Progressive Multiple Sclerosis according to GeneCards Suite gene sharing:

(show all 23)
id Name GO ID Score Top Affiliating Genes
1 inflammatory response GO:0006954 9.88 CSF1R IL10 PLP1 TNF
2 positive regulation of protein phosphorylation GO:0001934 9.79 CSF1R MMP9 TNF
3 regulation of cell shape GO:0008360 9.77 CSF1R ICAM1 S100B
4 cellular response to lipopolysaccharide GO:0071222 9.75 ICAM1 IL10 TNF
5 central nervous system development GO:0007417 9.73 MBP MOG S100B
6 response to glucocorticoid GO:0051384 9.63 IL10 S100B TNF
7 extracellular matrix organization GO:0030198 9.62 ICAM1 MMP9 TNF VCAM1
8 leukocyte cell-cell adhesion GO:0007159 9.61 ICAM1 VCAM1
9 B cell differentiation GO:0030183 9.61 IFNB1 IL10 VCAM1
10 osteoclast differentiation GO:0030316 9.6 CSF1R TNF
11 macrophage differentiation GO:0030225 9.57 CSF1R MMP9
12 negative regulation of growth of symbiont in host GO:0044130 9.55 IL10 TNF
13 leukocyte tethering or rolling GO:0050901 9.54 TNF VCAM1
14 positive regulation of heterotypic cell-cell adhesion GO:0034116 9.52 IL10 TNF
15 negative regulation of heterotypic cell-cell adhesion GO:0034115 9.51 IL10 MBP
16 axon ensheathment GO:0008366 9.49 MBP PLP1
17 endothelial cell apoptotic process GO:0072577 9.48 IL10 TNF
18 positive regulation of leukocyte adhesion to vascular endothelial cell GO:1904996 9.4 ICAM1 TNF
19 negative regulation of cytokine secretion involved in immune response GO:0002740 9.37 IL10 TNF
20 membrane to membrane docking GO:0022614 9.26 ICAM1 VCAM1
21 receptor biosynthetic process GO:0032800 9.16 IL10 TNF
22 B cell proliferation GO:0042100 9.13 IFNB1 IL10 IL7R
23 positive regulation of vascular smooth muscle cell proliferation GO:1904707 8.8 IL10 MMP9 TNF

Molecular functions related to Primary Progressive Multiple Sclerosis according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 structural constituent of myelin sheath GO:0019911 8.62 MBP PLP1

Sources for Primary Progressive Multiple Sclerosis

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....